Moxifloxacin Stulln Sine (Moxifloxacin)

Moxifloxacin is indicated for bacterial infections of the eye and related ocular tissues.

• Bacterial conjunctivitis: reduces bacterial load and resolves redness, discharge and irritation.
• Infectious keratitis: eradicates causative organisms and promotes corneal healing.
• Post‑operative ocular prophylaxis: prevents bacterial contamination following eye surgery.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. By binding to the quinolone‑resistance‑determining region of these enzymes, it prevents DNA strand separation, halting bacterial cell division and leading to bacterial death, providing bactericidal activity against a broad range of ocular pathogens.

Ocular administration of moxifloxacin may be associated with local and systemic adverse reactions.

Common Side Effects

• Stinging or burning sensation upon instillation.
• Temporary blurred vision.
• Redness of the conjunctiva.
• Tearing or discharge.
• Mild eye irritation.

Serious or Rare Side Effects

• Corneal ulceration or perforation.
• Severe allergic reaction (e.g., angioedema, anaphylaxis).
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Persistent intraocular inflammation.
• Vision loss.

Before prescribing moxifloxacin ophthalmic solution, clinicians should consider the following precautions.

• Allergy assessment: confirm no known hypersensitivity to fluoroquinolones or any component of the formulation.
• Contact lens wearers: advise removal of lenses before instillation and delay reinsertion until the eye is dry.
• Systemic fluoroquinolone use: avoid concurrent use to reduce risk of additive toxicity.
• Pregnancy and lactation: use only if the potential benefit outweighs the potential risk to the fetus or infant.
• Corneal epithelial defects: monitor closely as the drug may delay healing.
• Store at room temperature: keep in the original container, protect from moisture and light.

Moxifloxacin ophthalmic solution can interact with other medications, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Systemic fluoroquinolones: concurrent use may increase risk of tendon rupture and QT prolongation.
• Non‑steroidal anti‑inflammatory eye drops: may diminish antibacterial activity.

Moderate Interactions (Monitor Closely)

• Topical corticosteroids: may mask signs of infection and delay healing.
• Other ophthalmic antibiotics: co‑administration can lead to antagonism or resistance.
• Anticholinergic eye drops: may affect drug absorption.